CA3236793A1 - N-(4-aminocyclohexyl)pyrimidine-4-carboxamide derivatives as cd38 inhibitors - Google Patents

N-(4-aminocyclohexyl)pyrimidine-4-carboxamide derivatives as cd38 inhibitors Download PDF

Info

Publication number
CA3236793A1
CA3236793A1 CA3236793A CA3236793A CA3236793A1 CA 3236793 A1 CA3236793 A1 CA 3236793A1 CA 3236793 A CA3236793 A CA 3236793A CA 3236793 A CA3236793 A CA 3236793A CA 3236793 A1 CA3236793 A1 CA 3236793A1
Authority
CA
Canada
Prior art keywords
methyl
imidazol
mmol
carboxamide
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3236793A
Other languages
English (en)
French (fr)
Inventor
Roland Burli
Kevin Doyle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cerevance Inc
Original Assignee
Cerevance Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cerevance Inc filed Critical Cerevance Inc
Publication of CA3236793A1 publication Critical patent/CA3236793A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA3236793A 2021-11-09 2022-11-09 N-(4-aminocyclohexyl)pyrimidine-4-carboxamide derivatives as cd38 inhibitors Pending CA3236793A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2116077.5 2021-11-09
GB202116077 2021-11-09
PCT/GB2022/052833 WO2023084206A1 (en) 2021-11-09 2022-11-09 N-(4-aminocyclohexyl)pyrimidine-4-carboxamide derivatives as cd38 inhibitors

Publications (1)

Publication Number Publication Date
CA3236793A1 true CA3236793A1 (en) 2023-05-19

Family

ID=84360092

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3236793A Pending CA3236793A1 (en) 2021-11-09 2022-11-09 N-(4-aminocyclohexyl)pyrimidine-4-carboxamide derivatives as cd38 inhibitors

Country Status (6)

Country Link
US (1) US20250019369A1 (cg-RX-API-DMAC7.html)
EP (1) EP4430034A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024540318A (cg-RX-API-DMAC7.html)
CN (1) CN118317955A (cg-RX-API-DMAC7.html)
CA (1) CA3236793A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023084206A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4532483A1 (en) * 2022-06-02 2025-04-09 Aeovian Pharmaceuticals, Inc. Cd38 modulators and uses thereof
EP4724430A1 (en) * 2023-06-07 2026-04-15 Flagship Pioneering Innovations VI, LLC Condensed azines as inhibitors of cyclic adp ribose hydrolase
WO2026000074A1 (en) * 2024-06-25 2026-01-02 Welnx Company Inc. Use of cd38 inhibitors for reducing th2 inflammation
WO2026075971A1 (en) 2024-10-01 2026-04-09 Neolaia Inc. Combination therapy for treatment of metabolic disorders and inflamation related disorders using incretin compounds and cd38 inhibitors
WO2026090857A1 (zh) * 2024-10-29 2026-05-07 甫康(上海)健康科技有限责任公司 一种多取代的氨基喹啉类化合物及其用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11535621B2 (en) 2019-07-31 2022-12-27 Ribon Therapeutics, Inc. Heterobicyclic amides as inhibitors of CD38
KR20230051425A (ko) * 2020-04-07 2023-04-18 미토브리지, 인크. Cd38 억제제
CN117715897A (zh) * 2021-04-30 2024-03-15 南京艾美斐生物医药科技有限公司 化合物及其作为cd38抑制剂的用途

Also Published As

Publication number Publication date
EP4430034A1 (en) 2024-09-18
CN118317955A (zh) 2024-07-09
WO2023084206A1 (en) 2023-05-19
US20250019369A1 (en) 2025-01-16
JP2024540318A (ja) 2024-10-31

Similar Documents

Publication Publication Date Title
AU2020394444B2 (en) Substituted macrocyclic compounds and related methods of treatment
WO2023084206A1 (en) N-(4-aminocyclohexyl)pyrimidine-4-carboxamide derivatives as cd38 inhibitors
AU2016256917B2 (en) Histone deacetylase inhibitors and compositions and methods of use thereof
CA2930754C (en) Pyrazolopyridine derivatives as modulators of tnf activity
CA2481482C (en) Tropane derivatives as ccr5 modulators
EP2146959B1 (de) Vanilloid-rezeptor liganden und ihre verwendung zur herstellung von arzneimitteln
JP2022521536A (ja) イミダゾピリジニル化合物及び神経変性障害の処置のためのその使用
AU2016258188B2 (en) Histone deacetylase inhibitors and compositions and methods of use thereof
US20210078971A1 (en) Aryl heterocyclic piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists
WO2019241131A1 (en) Muscarinic acetylcholine m1 receptor antagonists
AU2005262330A1 (en) Piperidine derivatives as NK1 antagonists
IL259862A (en) Inhibitors of bruton's tyrosine kinase and methods of their use
EP4713323A1 (en) 3-carbonyl imidazo[1,5-a]pyridine derivatives for use as cd38 inhibitors for the treatment of cns disorders
CA3128421C (en) Janus Kinase (JAK) Family Inhibitor, its Preparation and Applications
JP2025541981A (ja) 縮合多環式化合物及びparp1阻害剤としてのそれらの使用
JP7592069B2 (ja) 抗マラリア性ヘキサヒドロピリミジン類似体
KR20230117460A (ko) 신규한 lrrk2 억제제
EP4421077A1 (en) Aryl or heteroaryl derivative, and pharmaceutical composition comprising same as active ingredient for prevention or treatment of kinase-related diseases
JP2024532729A (ja) フェロトーシス調節物質、その調製及び使用
EP4713322A1 (en) 1,3-thiazole and 1,2,4-thiadiazole derivatives for use as cd38 inhibitors for the treatment of cns disorders
AU2019218256A1 (en) Heterocyclic P2Y14 receptor antagonists
WO2023227867A1 (en) Heterobicyclic amides as inhibitors of cd38
TW202529754A (zh) Tyk2抑制劑及其用途
WO2023023670A1 (en) Compositions and methods of using the same for treatment of neurodegenerative and mitochondrial disease
JP2006511528A (ja) Nr2bレセプターアンタゴニストとしての2−ピリジル及び2−ピリミジルシクロアルキレンアミド化合物

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241104

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241104